Evidence map›Paper›PMID 33489939›Full record

ArticleFrontiers in cellular and infection microbiology2020

Genomic Epidemiology of Antimalarial Drug Resistance in

Fang Huang, Christopher G Jacob, Shannon Takala-Harrison, Matthew Adams, Heng-Lin Yang, Hui Liu, Zhi-Gui Xia, Shui-Sen Zhou, Lin-Hua Tang, Christopher V Plowe

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Fang HuangNational Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Chinese Center for Tropical Diseases Research, Key Laboratory of Parasite and Vector Biology, Ministry of Health, WHO Collaborating Centre for Tropical Diseases, National Center for International Research on Tropical Diseases, Shanghai, China.
Christopher G JacobMalaria Programme, Wellcome Sanger Institute, Cambridge, United Kingdom.
Shannon Takala-HarrisonCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, United States.
Matthew AdamsCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, United States.
Heng-Lin YangMalaria Department, Yunnan Institute of Parasitic Diseases, Puer, China.
Hui LiuMalaria Department, Yunnan Institute of Parasitic Diseases, Puer, China.
Zhi-Gui XiaNational Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Chinese Center for Tropical Diseases Research, Key Laboratory of Parasite and Vector Biology, Ministry of Health, WHO Collaborating Centre for Tropical Diseases, National Center for International Research on Tropical Diseases, Shanghai, China.
Shui-Sen ZhouNational Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Chinese Center for Tropical Diseases Research, Key Laboratory of Parasite and Vector Biology, Ministry of Health, WHO Collaborating Centre for Tropical Diseases, National Center for International Research on Tropical Diseases, Shanghai, China.
Lin-Hua TangNational Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Chinese Center for Tropical Diseases Research, Key Laboratory of Parasite and Vector Biology, Ministry of Health, WHO Collaborating Centre for Tropical Diseases, National Center for International Research on Tropical Diseases, Shanghai, China.
Christopher V PloweDuke Global Health Institute, Duke University, Durham, NC, United States.
National Institute for Parasitic Diseases · CNUniversity of Maryland, Baltimore · USYunnan Institute of Parasitic Diseases · CNDuke Institute for Health Innovation · USWellcome Sanger Institute · GB

Funding

Genome-wide studies to identify markers of artemisinin-resistant malariaR01AI101713 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI HARRISON, SHANNON TAKALA · 2013 to 2016
$1.8M
Identification and validation of molecular markers of piperaquine resistanceR01AI125579 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI HARRISON, SHANNON TAKALA · 2017 to 2021
$1.6M
Howard Hughes Medical InstituteNIAID NIH HHS R01 AI101713NIAID NIH HHS R01 AI125579
6 · The paper itself

Abstract

Emerging artemisinin resistance in Southeast Asia poses a significant risk to malaria control and eradication goals, including China's plan to eliminate malaria nationwide by 2020.

Indexed as

AntimalarialsMalaria, FalciparumChinaDrug ResistanceGenomicsHumansPlasmodium falciparumProtozoan ProteinsAntimalarialsProtozoan Proteinsantimalarial drugsartemisinin resistancemicroarraysPlasmodium falciparumSouthern China

Identifiers

PMID33489939
PMCPMC7820777
OpenAlexW3119517818

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.